UroGen CFO Degnan buys 2,281 shares
UroGen Pharma CFO Chris Degnan reported an acquisition of 2,281 shares in the company. The Form 4 shows the net acquired amount and a transaction price of $36.69 per share.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.